147 related articles for article (PubMed ID: 11354308)
21. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
Powis G; Wipf P; Lynch SM; Birmingham A; Kirkpatrick DL
Mol Cancer Ther; 2006 Mar; 5(3):630-6. PubMed ID: 16546977
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.
He J; Li D; Xiong K; Ge Y; Jin H; Zhang G; Hong M; Tian Y; Yin J; Zeng H
Bioorg Med Chem; 2012 Jun; 20(12):3816-27. PubMed ID: 22579620
[TBL] [Abstract][Full Text] [Related]
23. Cobaltoceniumethynyl gold(I) as an unusual heterodinuclear bioorganometallic fragment to study the biological properties of alkynyl gold complexes.
Vanicek S; Kopacka H; Wurst K; Vergeiner S; Kankowski S; Schur J; Bildstein B; Ott I
Dalton Trans; 2016 Jan; 45(4):1345-8. PubMed ID: 26732365
[TBL] [Abstract][Full Text] [Related]
24. Targeting thioredoxin reductase: anticancer agents and chemopreventive compounds.
Zeng HH; Wang LH
Med Chem; 2010 Sep; 6(5):286-97. PubMed ID: 20977412
[TBL] [Abstract][Full Text] [Related]
25. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
[TBL] [Abstract][Full Text] [Related]
26. Human thioredoxin reductase is efficiently inhibited by (2,2':6',2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy.
Becker K; Herold-Mende C; Park JJ; Lowe G; Schirmer RH
J Med Chem; 2001 Aug; 44(17):2784-92. PubMed ID: 11495589
[TBL] [Abstract][Full Text] [Related]
27. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
28. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
31. Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung.
Ozgencli I; Budak H; Ciftci M; Anar M
Anticancer Agents Med Chem; 2018; 18(11):1599-1605. PubMed ID: 29793415
[TBL] [Abstract][Full Text] [Related]
32. The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition.
Reiser K; Mathys L; Curbo S; Pannecouque C; Noppen S; Liekens S; Engman L; Lundberg M; Balzarini J; Karlsson A
PLoS One; 2016; 11(1):e0147773. PubMed ID: 26816344
[TBL] [Abstract][Full Text] [Related]
33. Gold(I) N-heterocyclic carbene complexes with naphthalimide ligands as combined thioredoxin reductase inhibitors and DNA intercalators.
Meyer A; Oehninger L; Geldmacher Y; Alborzinia H; Wölfl S; Sheldrick WS; Ott I
ChemMedChem; 2014 Aug; 9(8):1794-800. PubMed ID: 24803348
[TBL] [Abstract][Full Text] [Related]
34. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity.
Chew EH; Lu J; Bradshaw TD; Holmgren A
FASEB J; 2008 Jun; 22(6):2072-83. PubMed ID: 18180330
[TBL] [Abstract][Full Text] [Related]
35. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.
Hickey JL; Ruhayel RA; Barnard PJ; Baker MV; Berners-Price SJ; Filipovska A
J Am Chem Soc; 2008 Sep; 130(38):12570-1. PubMed ID: 18729360
[TBL] [Abstract][Full Text] [Related]
36. A Photoactive Platinum(IV) Anticancer Complex Inhibits Thioredoxin-Thioredoxin Reductase System Activity by Induced Oxidization of the Protein.
Du J; Wei Y; Zhao Y; Xu F; Wang Y; Zheng W; Luo Q; Wang M; Wang F
Inorg Chem; 2018 May; 57(9):5575-5584. PubMed ID: 29688719
[TBL] [Abstract][Full Text] [Related]
37. Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins.
Navakoski de Oliveira K; Andermark V; von Grafenstein S; Onambele LA; Dahl G; Rubbiani R; Wolber G; Gabbiani C; Messori L; Prokop A; Ott I
ChemMedChem; 2013 Feb; 8(2):256-64. PubMed ID: 23281101
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity.
Mau BL; Powis G
Biochem Pharmacol; 1992 Apr; 43(7):1621-7. PubMed ID: 1567483
[TBL] [Abstract][Full Text] [Related]
39. Small Molecules to Target the Selenoprotein Thioredoxin Reductase.
Zhang B; Liu Y; Li X; Xu J; Fang J
Chem Asian J; 2018 Dec; 13(23):3593-3600. PubMed ID: 30204305
[TBL] [Abstract][Full Text] [Related]
40. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.
Oblong JE; Chantler EL; Gallegos A; Kirkpatrick DL; Chen T; Marshall N; Powis G
Cancer Chemother Pharmacol; 1994; 34(5):434-8. PubMed ID: 8070012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
